U.S., May 28 -- ClinicalTrials.gov registry received information related to the study (NCT07610005) titled 'A Relative Bioavailability and Bioequivalence Study of Varegacestat in Healthy Participants' on May 20.
Brief Summary: This is an open-label, randomized, crossover study to evaluate the relative bioavailability (rBA) and bioequivalence (BE) of a test capsule formulation of varegacestat compared to reference capsules formulation under fasting conditions.
Study Start Date: June, 2026
Study Type: INTERVENTIONAL
Condition:
Healthy
Intervention:
DRUG: Varegacestat Reference Formulation
Oral administration
DRUG: Varegacestat Test Formulation
Oral administration
Recruitment Status: RECRUITING
Sponsor: Immunome, Inc.
Published by...